Charles Carter - CERo Therapeutics Treasurer CFO
| CERO Stock | 0.07 0.01 8.42% |
CFO
Charles Carter is Treasurer CFO of CERo Therapeutics Holdings,
| Age | 57 |
| Address | 201 Haskins Way, South San Francisco, CA, United States, 94080 |
| Phone | 215 731 9450 |
| Web | https://www.cero.bio |
CERo Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4528) % which means that it has lost $0.4528 on every $100 spent on assets. This is way below average. CERo Therapeutics' management efficiency ratios could be used to measure how well CERo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 13th of December 2024, Return On Equity is likely to grow to 0.0002, while Return On Tangible Assets are likely to drop (0.0003). At this time, CERo Therapeutics' Other Current Assets are very stable compared to the past year. As of the 13th of December 2024, Debt To Assets is likely to grow to 0.19, while Total Assets are likely to drop about 8.1 M.Similar Executives
| Found 2 records | CFO Age | ||
| Matti Masanovich | Catalent | 52 | |
| Sameer Parasnis | WT Offshore | 49 | |
Management Performance
| Return On Asset | -0.45 |
CERo Therapeutics Leadership Team
Elected by the shareholders, the CERo Therapeutics' board of directors comprises two types of representatives: CERo Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CERo. The board's role is to monitor CERo Therapeutics' management team and ensure that shareholders' interests are well served. CERo Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CERo Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles Carter, Treasurer CFO | ||
| Daniel MD, CTO Founder | ||
| Christopher MBA, Interim Chairman | ||
| Brian Atwood, President Director | ||
| Lawrence MD, Cofounder Board | ||
| Andrew MBA, Chief Officer | ||
| Kristen Pierce, Chief Director |
CERo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CERo Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.45 | ||||
| Current Valuation | 12.73 M | ||||
| Shares Outstanding | 51.35 M | ||||
| Shares Owned By Insiders | 12.54 % | ||||
| Shares Owned By Institutions | 9.04 % | ||||
| Number Of Shares Shorted | 5.83 M | ||||
| EBITDA | (2.44 M) | ||||
| Net Income | (2.54 K) | ||||
| Total Debt | 1.55 M | ||||
| Book Value Per Share | (0.52) X |
Pair Trading with CERo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CERo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CERo Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against CERo Stock
| 0.71 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.66 | LLY | Eli Lilly | PairCorr |
| 0.59 | VALN | Valneva SE ADR | PairCorr |
| 0.58 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.57 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
The ability to find closely correlated positions to CERo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CERo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CERo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CERo Therapeutics Holdings, to buy it.
The correlation of CERo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CERo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CERo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CERo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CERo Therapeutics Holdings,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CERo Therapeutics. If investors know CERo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CERo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.19) | Return On Assets (0.45) |
The market value of CERo Therapeutics is measured differently than its book value, which is the value of CERo that is recorded on the company's balance sheet. Investors also form their own opinion of CERo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CERo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CERo Therapeutics' market value can be influenced by many factors that don't directly affect CERo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CERo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CERo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CERo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.